Business context and reporting period
Filing identity: The supplied 10-Q is for Angion Biomedica Corp. (ticker ANGN), not Elicio Therapeutics, Inc. It covers the quarter ended March 31, 2023. Angion had suspended most clinical development while pursuing an all-stock merger with Elicio, announced January 17, 2023. The proposed combined company was expected to focus on Elicio’s immunotherapy platform, including ELI-002.
Key financial results
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | $0 | $1.648 million |
| Research and development expense | $0.326 million | $11.667 million |
| General and administrative expense | $4.281 million | $4.466 million |
| Operating loss | $4.607 million | $14.485 million |
| Net loss | $4.537 million | $14.240 million |
| Net loss per share | $0.15 | $0.48 |
| Cash used in operating activities | $8.079 million | $15.653 million |
At March 31, 2023, cash and cash equivalents were $29.219 million, down from $50.487 million at year-end 2022. Current assets were $40.627 million and current liabilities were $2.031 million. Total liabilities were $2.101 million; the financing obligation was terminated during the quarter. Angion reported no product sales, so revenue-based margins are not meaningful.
Changes, unusual items, and outlook
- Net loss narrowed by $9.703 million year over year, primarily reflecting a $11.341 million reduction in R&D expense after clinical programs ended or were suspended. G&A declined 4%; merger-related legal costs partly offset other reductions. The 2022 comparison included $1.648 million of Vifor contract revenue; Angion completed its related performance obligations in 2022.
- Investing cash outflow included a $10 million bridge loan to Elicio. The loan notes had $12.5 million aggregate principal capacity, a 20% original issue discount, and a one-year maturity; their March 31 fair value was $9.678 million. Fair-value changes are reflected in earnings.
- Financing cash outflow was $3.268 million, mainly a $3.025 million payment to terminate the NovaPark lease and $0.228 million to terminate a sale-leaseback financing arrangement. Lease surrender relieved approximately $3.86 million of future rent, plus certain facility and utility charges.
- Angion said existing cash was expected to fund planned operations for at least 12 months after issuance of the statements, well into 2024. Management reported no substantial doubt about going concern, but noted projections could prove incorrect and additional financing might be needed.
- Angion transferred substantially all cash from Silicon Valley Bank to an asset manager at March-end after SVB’s closure. The filing describes temporary liquidity and credit exposure before the FDIC resolution.
- Angion did not expect Vifor milestones or royalties because it did not plan to continue the ANG-3777 clinical development plan. Its prior ANG-3777 Phase 3 DGF and Phase 2 CSA-AKI trials missed primary endpoints; the ANG-3070 JUNIPER trial was terminated following safety and risk-benefit reassessment.
Risks and contingencies
Completion of the Elicio merger was uncertain and subject to conditions. Merger-related litigation could delay or prevent closing; a shareholder lawsuit filed in February was voluntarily dismissed, but the company warned further challenges could arise. Angion also cited dependence on external financing, development and regulatory uncertainty, and reliance on third-party manufacturers and service providers. The filing states disclosure controls were effective as of March 31, 2023.
Important facts for investors to verify
- Merger status, closing conditions, and the resulting ownership and financing arrangements.
- Cash runway assumptions, cash custody following the SVB transfer, and any subsequent financing needs.
- Collectability and valuation of the Elicio notes receivable, including their repayment or treatment if the merger does not close.
- Whether any clinical development resumes if the merger fails, and the costs and funding required.
- Any new merger-related litigation or other material contingencies.